Cargando…
Blockade of high mobility group box 1 augments antitumor T‐cell response induced by peptide vaccination as a co‐adjuvant
High mobility group box 1 (HMGB1) is a member of the family of damage‐associated molecular patterns, which cause inflammation and trigger innate immunity through Toll‐like receptors 2/4 and the receptor for advanced glycation end products. We examined the effect of glycyrrhizin, a selective inhibito...
Autores principales: | Waki, Kayoko, Yamada, Akira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198958/ https://www.ncbi.nlm.nih.gov/pubmed/27717108 http://dx.doi.org/10.1111/cas.13084 |
Ejemplares similares
-
Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer
por: Waki, Kayoko, et al.
Publicado: (2017) -
Suppression of high mobility group box 1 in B16F10 tumor does not inhibit the induction of neoantigen‐specific T cells
por: Waki, Kayoko, et al.
Publicado: (2022) -
Knockout of high-mobility group box 1 in B16F10 melanoma cells induced host immunity-mediated suppression of in vivo tumor growth
por: Yokomizo, Kanako, et al.
Publicado: (2022) -
Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients
por: Waki, Kayoko, et al.
Publicado: (2020) -
Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine
por: Koga, Noriko, et al.
Publicado: (2017)